


**AMENDMENTS TO THE CLAIMS:**

1-34 (Canceled).

35. (New) A chemical compound of formula (I):



wherein:

R<sub>1</sub> to R<sub>3</sub> are independently selected from hydrogen and lower alkyl;

X<sub>1</sub> is selected from N and C-R<sub>4</sub>;

X<sub>2</sub> is selected from N and C-R<sub>5</sub>;

X<sub>3</sub> is selected from N and C-R<sub>6</sub>;

X<sub>4</sub> is selected from N and C-R<sub>7</sub>;

wherein only one of X<sub>1</sub> to X<sub>4</sub> is N;

R<sub>4</sub>, R<sub>5</sub> and R<sub>7</sub> are independently selected from hydrogen, halogen, hydroxy, alkyl, aryl, alkoxy, aryloxy, alkoyl, aryloyl, alkylthio, arylthio, alkylsulfoxyl, arylsulfoxyl, alkylsulfonyl, arylsulfonyl, amino, alkylamino, dialkylamino, nitro, cyano, carboalkoxy, carboaryloxy and carboxy; and

R<sub>6</sub> is selected from hydrogen, halogen, alkyl, aryl, aryloxy, alkylthio, arylthio, alkylsulfoxyl, arylsulfoxyl, alkylsulfonyl, arylsulfonyl, amino, alkylamino, dialkylamino and cyano;

with the proviso that R<sub>4</sub> to R<sub>7</sub> are not all selected as hydrogen,

or a pharmaceutically acceptable salt, addition compound or prodrug thereof.

36. (New) A compound according to claim 35, wherein R<sub>1</sub> is selected from hydrogen and methyl.

37. (New) A compound according to claim 35, wherein R<sub>2</sub> is hydrogen.

38. (New) A compound according to claim 35, wherein R<sub>3</sub> is selected from hydrogen and methyl.

39. (New) A compound according to claim 35, wherein X<sub>2</sub> is C-R<sub>5</sub>.

40. (New) A compound according to claim 35, wherein X<sub>3</sub> is C-R<sub>6</sub>.

41. (New) A compound according to claim 35, wherein X<sub>4</sub> is C-R<sub>7</sub>.

42. (New) A compound according to claim 35, wherein X<sub>1</sub> is C-R<sub>4</sub>.

43. (New) A compound according to claim 35, wherein two of R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub> and R<sub>7</sub> are hydrogen.

44. (New) A compound according to claim 43, wherein R<sub>4</sub> and R<sub>6</sub> are hydrogen.

45. (New) A compound according to claim 35, wherein two of R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub> and R<sub>7</sub> are independently selected from hydrogen, chlorine, fluorine, trifluoromethyl and bromine.

46. (New) A compound according to claim 35, wherein three of R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub> and R<sub>7</sub> are hydrogen.

47. (New) A compound according to claim 46, wherein R<sub>4</sub>, R<sub>6</sub> and R<sub>7</sub> are hydrogen.

48. (New) A compound according to claim 35, wherein R<sub>4</sub> is hydrogen.

49. (New) A compound according to claim 35, wherein R<sub>5</sub> is halogen.

50. (New) A compound according to claim 35, wherein R<sub>6</sub> is hydrogen.


51. (New) A compound according to claim 35, wherein R<sub>7</sub> is halogen.
52. (New) A compound according to claim 35, wherein the compound is:  
(RS) 7-Chloro-1,2,3,4,10,10a-hexahydro-6-aza-pyrazino[1,2-a]indole fummarate.
53. (New) A method of treatment of disorders of the central nervous system; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes insipidus, and sleep apnea comprising administering to a patient in need of such treatment an effective does of a compound of formula (I) as set out in claim 35.
54. (New) A method according to claim 53, wherein the disorders of the central nervous system are selected from depression, atypical depression, bipolar disorders, anxiety disorders, obsessive-compulsive disorders, social phobias or panic states, sleep disorders, sexual dysfunction, psychoses, schizophrenia, migraine and other conditions associated with cephalic pain or other pain, raised intracranial pressure, epilepsy, personality disorders, age-related behavioural disorders, behavioural disorders associated with dementia, organic mental disorders, mental disorders in childhood, aggressivity, age-related memory disorders, chronic fatigue syndrome, drug and alcohol addiction, obesity, bulimia, anorexia nervosa and premenstrual tension.
55. (New) A method according to claim 53, wherein the damage to the central nervous system is by trauma, stroke, neurodegenerative diseases or toxic or infective CNS diseases.
56. (New) A method according to claim 55, wherein said toxic or infective CNS disease is encephalitis or meningitis.
57. (New) A method according to claim 53, wherein the cardiovascular disorder is thrombosis.
58. (New) A method according to claim 53, wherein the gastrointestinal disorder is dysfunction of gastrointestinal motility.
59. (New) A method according to claim 53, wherein said disorder is obesity.

60. (New) A pharmaceutical composition comprising a compound of formula (I) as set out in claim 35 in combination with a pharmaceutically acceptable carrier or excipient.

61. (New) A method of making a pharmaceutical composition comprising combining a compound of formula (I) as set out in claim 35 with a pharmaceutically acceptable carrier or excipient.

62. (New) A process for the preparation of a compound of formula (I) according to claim 35, said process comprising the steps of:

(i) treating a compound of formula (IX) with an aldehyde of formula RCHO and then exposing the compound to acid to obtain a compound of formula (X), wherein X<sub>1</sub>, X<sub>2</sub>, X<sub>3</sub>, X<sub>4</sub>, R<sub>2</sub> and R<sub>3</sub> are as described in claim 35, and



(ii) reduction of a compound of formula (X).